Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Europese goedkeuring pembrolizumab voor behandeling van recidief of refractair klassiek HL
mei 2017 | Lymfoom